The cyclooxygenase-2 inhibitors: Safety and effectiveness

Annals of Pharmacotherapy

Volumn 33, Issue 9, 1999, Pages 979-988

  Kaplan Machlis, Barbara ^a   Klostermeyer, Barbara Storyk ^b,c  

^a WEST VIRGINIA UNIVERSITY   (United States)

^b WEST VIRGINIA UNIVERSITY   (United States)

^c FLORIDA HOSPITAL   (United States)

Author keywords

And MK 966; Celecoxib; COX 2 inhibitors; Cyclooxygenase 2 inhibitors; Flosulide; Meloxicam; Rofecoxib; SC 58635

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; FLOSULIDE; MELOXICAM; ROFECOXIB; UNCLASSIFIED DRUG;

ARTHRITIS; ARTICLE; DRUG EFFICACY; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; HUMAN; INFLAMMATION; MITOGENESIS; MUSCULOSKELETAL INJURY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; HUMANS; ISOENZYMES; MEMBRANE PROTEINS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES;

EID: 0032863397     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.18415     Document Type: Article

References (59)

1. McCarthy D. Nonsteroidal anti-inflammatory drug-related gastrointestinal toxicity: definitions and epidemiology. Am J Med 1998;105(suppl 3A):3S-9S.
2. Lanza FL, and the Members of the Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology. A guideline for the treatment and prevention of NSAID-induced ulcers. Am J Gastroenterol 1998;93:2037-46.
3. Silverstein FE, Graham DY, Senior JR, Davies HW, Struthers BJ, Bittman RM, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995;123:241-9.
4. DeWitt DL, Meade E, Smith WL. PGH synthase isoenzyme selectivity: the potential for safer nonsteroidal anti-inflammatory drugs. Am J Med 1993;95(suppl):40S-4S.
5. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for the aspirin-like drugs. Nature 1971;231:232-5.
6. Marnett L. Aspirin and the potential role for prostaglandins in colon cancer. Cancer Res 1992;52:5575-89.
7. Smith WL, Marnett LJ. Prostaglandin endoperoxide synthase: structure and catalysis. Biochem Biophys Acta 1991;1083:1-17.
8. Campbell WB. Lipid-derived autacoids: eicosanoids and platelet-activating factor. In: Goodman Gilman A, Rall TW, Nies AS, Taylor P, eds. Goodman and Gilman's the pharmacological basis of therapeutics. 8th ed. Elmsford, NY: Pergamon Press, 1990:600-17.
9. Smith WL, Garavito RM, DeWitt DL. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J Biol Chem 1996;271:331-57.
10. Fu J-Y, Masferrer JL, Seibert K, Raz A, Needleman P. The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes. J Biol Chem 1990;265:16737-40.
11. Xie W, Robertson DL, Simmons DL. Mitogen-inducible prostaglandin G/H synthase: a new target for nonsteroidal antiinflammatory drugs. Drug Dev Res 1992;25:249-65.
12. Donnelly MT, Hawkey CJ. Review article: COX-II inhibitors - a new generation of safer NSAIDs? Aliment Pharmacol Ther 1997;11:227-36.
13. Siegle I, Klein T, Backman JT, Saul JG, Nusing RM, Fritz P, et al. Expression of cyclooxygenase 1 and cyclooxygenase 2 in human synovial tissue. Differential elevation of cyclooxygenase 2 in inflammatory joint diseases. Arthritis Rheum 1998;41:122-9.
14. Famaey JP. In vitro and in vivo pharmacological evidence of selective cyclooxygenase-2 inhibition by nimesulide: an overview. Inflamm Res 1997;46:437-46.
15. Spangler RS. Cyclooxygenase 1 and 2 in rheumatic disease: implications for nonsteroidal anti-inflammatory drug therapy. Semin Arthritis Rheum 1996;26:436-47.
16. Barnett J, Chow J, Ives D, Chiou M, Mackenzie R, Osen E, et al. Purification, characterization and selective inhibition of human prostaglandin G/H synthase 1 and 2 expressed in the baculovirus system. Biochem Biophys Acta 1994;1209:130-9.
17. Crankshaw DJ, Dyal R. Effects of some naturally occurring prostanoids and some cyclooxygenase inhibitors on the contraction of the human uterine segment in vivo. Can J Physiol Pharmacol 1994;72:870-4.
18. Harris RC, McKanna JA, Akai Y, Jacobson HR, Dubois RN, Breyer MD, et al. Cyclooxygenase-2 is associated with the macula densa of the kidney and increases with salt restriction. J Clin Invest 1994;94:2504-10.
19. Wolfe MM. Future trends in the development of safer nonsteroidal anti-inflammatory drugs. Am J Med 1998;105(suppl 5A):44S-52S.
20. Brunel P, Hornych A, Guyene TT, Sioufi A, Turri M, Menard J, et al. Renal and endocrine effects of flosulide, after single and repeated administration to healthy volunteers. Eur J Clin Pharmacol 1995;49:193-201.
21. McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, FitzGerald GA, et al. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci U S A 1999;96:272-7.
22. Stichtenoth DO, Wagner B, Frolich JC. Effects of meloxicam and indomethacin on cyclooxygenase pathways in healthy volunteers. J Investig Med 1997;45:44-9.
23. Turck D, Busch U, Heinzel G, Narjes H. Clinical pharmacokinetics of meloxicam. Arzneimittelforschung 1997;47:253-8.
24. Noble S, Balfour JA. Meloxicam. Drugs 1996;3:424-30.
25. Bassleer C, Magorteaux J, Geenen V, Malaise M. Effects of meloxicam compared to acetylsalicylic acid in human articular chondrocytes. Pharmacology 1997;54:49-56.
26. Chesne C, Guyomard C, Guillouzoi A, Schmid J, Ludwig E, Sauter T, et al. Metabolism of meloxicam in human liver involves cytochromes P4502C9 and 3A4. Xenobiotica 1998;28:1-13.
27. Turck D, Su CAPF, Heinzel G, Busch U, Bluhmki E, Hoffman J, et al. Lack of interaction between meloxicam and warfarin in healthy volunteers. Eur J Clin Pharmacol 1997;51:421-5.
28. Busch U, Heinzel G, Narjes H, Nehmiz G. Interaction of meloxicam with cimetidine, Maalox, or aspirin. J Clin Pharmacol 1996;36:79-84.
29. Muller FO, Schall R, de Vaal AC, Groenewoud G, Hundt HK, Middle MV, et al. Influence of meloxicam on furosemide pharmacokinetics and pharmacodynamics in healthy volunteers. Eur J Clin Pharmacol 1995; 48:247-51.
30. Degner FL, Heinzel G, Narjes H, Turck D. The effect of meloxicam on the pharmacokinetics of beta-acetyl digoxin. Br J Clin Pharmacol 1995; 40:486-8.
31. Busch U, Heinzel G, Narjes H. The effect of cholestyramine on the pharmacokinetics of meloxicam, a new non-steroidal anti-inflammatory drug (NSAID), in man. Eur J Clin Pharmacol 1995;48:269-72.
32. Bosch HC, Sigmund R, Hettich M. Efficacy and tolerability of intramuscular and oral meloxicam in patients with acute lumbago: a comparison with intramuscular and oral piroxicam. Curr Med Res Opin 1997;14:29-38.
33. Auvinet B, Ziller R, Appelboom T, Velicitat P. Comparison of the onset and intensity of action of intramuscular meloxicam and oral meloxicam in patients with acute sciatica. Clin Ther 1995;17:1078-90.
34. Lund B, Distel M, Bluhmki E. A double-blind, randomized, placebo controlled study of efficacy and tolerance of meloxicam treatment of patients with osteoarthritis of the knee. Scand J Rheumatol 1998;27:32-7.
35. Lemmel EM, Bolten W, Burgos-Vargas R, Platt P, Nissila M, Sahlberg D, et al. Efficacy and safety of meloxicam in patients with rheumatoid arthritis. J Rheumatol 1997;24:282-90.
36. Distel M, Mueller C, Bluhmki E, Fries J. Safety of meloxicam: a global analysis of clinical trials. Br J Rheumatol 1996;35(suppl 1):68-77.
37. Ghozlan PR, Bernhardt M, Velicitat P, Bluhmki E. Tolerability of multiple administration of intramuscular meloxicam: a comparison with intramuscular piroxicam in patients with rheumatoid arthritis or osteoarthritis. Br J Rheumatol 1996;35(suppl 1):51-5.
38. Linden B, Distel M, Bluhmki E. A double-blind study to compare the efficacy and safety of meloxicam 15 mg with piroxicam 20 mg in patients with osteoarthritis of the hip. Br J Rheumatol 1996;35(suppl 1):35-8.
39. Hosie J, Distel M, Bluhmki E. Efficacy and tolerability of meloxicam versus piroxicam in patients with osteoarthritis of the hip or knee: a six-month double blind study. Clin Drug Invest 1997;13:175-84.
40. Dequeker J, Hawkey C, Kahan A, Steinbruck K, Alegre C, Baumelous E, et al. Improvement in gastrointestinal tolerability of the selective cyclooxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: results of the safety and efficacy large-scale evaluation of COX-inhibiting therapies (SELECT) trial in osteoarthritis. Br J Rheumatol 1998;37: 946-51.
41. Goei H, Lund B, Distel M, Bluhmki E. A double-blind, randomized trial to compare meloxicam 15 mg with diclofenac 100 mg in the treatment of osteoarthritis of the knee. Osteoarthritis Cartilage 1997;5:283-8.
42. Hosie J, Distel M, Bluhmki E. Meloxicam in osteoarthritis: a six month, double-blind comparison with diclofenac sodium. Br J Rheumatol 1996; 35(suppl 1):39-43.
43. Hawkey C, Kahan A, Steinbruck K, Alegre C, Baumelous E, Begaud B, et al. Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. Br J Rheumatol 1998;37:937-45.
44. Wojtulewski JA, Schattenkirchener M, Barcelo P, Le Lout X, Bevis PJ, Bluhmki E, et al. A six-month double blind trial to compare the efficacy and safety of meloxicam 7.5 mg daily and naproxen 750 mg daily in patients with rheumatoid arthritis. Br J Rheumatol 1996;35(suppl 1):22-8.
45. Lipsky PE, Isaakson PC. Outcome of specific COX-2 inhibition in rheumatoid arthritis. J Rheumatol 1997;24(suppl 49):9-14.
46. Simon LS, Lanza FL, Lipsky PE, Hubbard RC, Talwaker S, Schwartz BD, et al. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. Arthritis Rheum 1998;41:1591-602.
47. Kawamori T, Chinthalapally RV, Seibert K, Reddy BS. Chemoprotective activity of celecoxib, a specific cyclooxygenase-2 inhibitor against colon carcinogenesis. Cancer Res 1998;58:409-12.
48. Product information. Celebrex (celecoxib capsules). New York: GD Searle & Co., 1998.
49. Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of hip or knee. J Rheumatol 1988;15:1833-40.
50. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
51. Mengle-Gaw L, Hubbard RC, Karim A. A study of the platelet effects of SC-58635, a novel COX-2 selective inhibitor (abstract). Arthritis Rheum 1997;40(suppl):S93,374A.
52. Garcia Rodriguez LA. Nonsteroidal antiinflammatory drugs, ulcers and risk: a collaborative meta-analysis. Semin Arthritis Rheum 1997;26(6 suppl 1):16-20.
53. American College of Rhemuatology, 1998 Annual Meeting, San Diego, CA, November 8-12, 1998.
54. Product information. Vioxx (rofecoxib tablets and oral suspension). West Point, PA: Merck & Co., Inc., 1999.
55. Cannon G, Caldwell J, Holt P, McLean B, Zing Q, Ehrich E, et al. MK0966, a specific COX-2 inhibitor, has clinical efficacy comparable to diclofenac in the treatment of hip and knee osteoarthritis (OA) in a 26-week controlled clinical trial (abstract). American College of Rheumatology. 1998 Annual Meeting, San Diego, CA, November 8-12, 1998.
56. Saag K, Fisher C, McKay J, Ehrich E, Zhao PL, Bolognese J, et al. MK-0966, a specific COX-2 inhibitor, has clinical efficacy comparable to ibuprofen in the treatment of knee and hip osteoarthritis (OA) in a 6-week controlled clinical trial (abstract). American College of Rheumatology, 1998 Annual Meeting, San Diego, CA, November 8-12, 1998.
57. Maetzel A, Bombardier C. An examination of the cost effectiveness potential of cyclooxygenase-2 selective antiinflammalory drugs (abstract). American College of Rheumatology, 1998 Annual Meeting, San Diego, CA, November 10, 1998.
58. 1999 Drug topics red book. Montvale, NJ: Medical Economics Company, 1999.
59. Company news on call. Searle response to Wall Street Journal story regarding Celebrex, April 21, 1999. Available at: www.prnewswire.com. Accessed July 29, 1999.